TuisPSTV • NASDAQ
add
Plus Therapeutics Inc
Vorige sluiting
$0,32
Dagwisseling
$0,29 - $0,32
Jaarwisseling
$0,16 - $2,31
Markkapitalisasie
56,53 m USD
Gemiddelde volume
15,14 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 1,40 m | -4,05% |
Bedryfskoste | 3,44 m | 43,64% |
Netto inkomste | -4,42 m | -53,90% |
Netto winsgrens | -316,61 | -60,40% |
Wins per aandeel | -0,04 | 89,19% |
EBITDA | -4,40 m | -22,36% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 16,60 m | 246,72% |
Totale bates | 18,67 m | 167,56% |
Totale aanspreeklikheid | 13,62 m | 12,05% |
Totale ekwiteit | 5,05 m | — |
Uitstaande aandele | 137,43 m | — |
Prys om te bespreek | 8,11 | — |
Opbrengs op bates | -77,22% | — |
Opbrengs op kapitaal | -154,14% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -4,42 m | -53,90% |
Kontant van bedrywe | -2,55 m | 30,76% |
Kontant van beleggings | 1,30 m | 14 511,11% |
Kontant van finansiering | 12,31 m | — |
Netto kontantverandering | 11,06 m | 399,70% |
Beskikbare kontantvloei | -972,25 k | 88,40% |
Meer oor
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecular diagnostic service, CNSide®. Wikipedia
Gestig
1996
Hoofkwartier
Webwerf
Werknemers
21
